CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...
Phase 3
Philadelphia, Pennsylvania, United States and 66 other locations
and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...
Phase 1, Phase 2
Wilmington, Delaware, United States and 73 other locations
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non...
Phase 1
Philadelphia, Pennsylvania, United States and 33 other locations
in participants with relapsed or refractory (R/R) solid tumors or non-Hodgkin lymphoma (NHL).Part 2: Cohort Expansion. The...
Phase 1, Phase 2
Philadelphia, Pennsylvania, United States and 25 other locations
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...
Phase 2
Philadelphia, Pennsylvania, United States and 55 other locations
The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non...
Phase 1
Philadelphia, Pennsylvania, United States and 2 other locations
This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin L....
Phase 1
Philadelphia, Pennsylvania, United States of America and 7 other locations
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The ma...
Phase 1
Philadelphia, Pennsylvania, United States and 14 other locations
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...
Phase 2
Philadelphia, Pennsylvania, United States and 74 other locations
This study will enroll approximately 160 adult participants who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicab...
Phase 2
Philadelphia, Pennsylvania, United States of America and 18 other locations
Clinical trials
Research sites
Resources
Legal